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OBJECTIVES: Patient-reported outcomes (PROs) are critical to advancing patient 
centered care (PCC). Recording PROs in real-time represents the most direct and 
accurate assessment of disease and treatment impact. However, the collection of 
PROs in real-time, where they can best influence disease management, is challeng-
ing. We report real-time PRO collection at point of care in patients with rheumatoid 
arthritis (RA) through use of a decision support tool (DST). METHODS: From 1/1/2012 
to 12/31/2013, 79 rheumatologists in 35 practices participating in a payer-sponsored 
rheumatologist-developed RA pathway program incorporated use of a point-of-care 
DST, which required a clinical disease activity index (CDAI) assessment at each 
physician visit. The CDAI is comprised of 4 components: swollen joint count (SJC), 
tender joint count (TJC), physician global assessment (PhGA), and patient global 
assessment (PGA). Patient rates of CDAI reporting and their correlation to CDAI score 
were calculated. CDAI disease burden interpretation: ≤ 2.8 remission, CDAI 2.9-10 
low, 10.1-22 moderate, 22.1-76 high. RESULTS: 3185 active patients, defined as ≥ 2 
physician visits over the study period, contributed PRO information for 13,723 visits. 
At least 1 CDAI component was documented in 90% of visits. PGA and PhGA were 
both documented in 66% of visits. SJC and TJC were least likely to be documented. 
Almost all patients (99%) not in remission, with a CDAI score greater ≥ 2.8, had all 
4 CDAI components documented. CONCLUSIONS: PROs at point of care is a neces-
sary component for full realization of PCC. We have demonstrated the feasibility 
of collecting real-time PROs from patients with RA during physician visits. For 99% 
of patients who were not in remission, all 4 components of CDAI were captured at 
a high rate by DST. A 90% rate of documentation for any CDAI component demon-
strates the ease and potential for point of care data collection via DST.
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OBJECTIVES: Managing high-cost and highly toxic orphan and ultra-orphan drugs 
of precision medicine presents medication therapy management (MTM) problems 
for payers and their pharmacy benefit management and specialty pharmacy ven-
dors who increasingly leverage volume throughput to lower cost. The rapid expan-
sion of this drug class, fragmentation between pharmacy and medical benefit, and 
increasing use of pathways-based disease management add urgency to finding a 
solution to these problems. Patient-reported outcomes (PROs) may be the most 
direct and accurate assessment of disease and treatment impact. We report on 
an MTM pilot program using a PRO-based intervention algorithm. METHODS: 
OncoSource Rx (OSRx), a wholly owned specialty pharmacy of Cardinal Health, 
conducted a 1-month pilot study of a novel PRO-based MTM solution in conjunc-
tion with a regional Mid-Atlantic insurer. Patient-risk stratification by diagnosis 
and drug resulted in a scripted pharmacy technician phone call triage. All patients 
were contacted at initial fill of a specialty pharmacy prescription and periodically 
thereafter based on their risk profile. Patient queries were designed to identify 
barriers to medication possession RESULTS: From 3/1/14 to 3/31/14, OSRx received 
specialty pharmacy prescriptions directly from providers for 239 patients with either 
a rheumatologic or oncologic diagnosis. A total of 956 phone calls by pharmacy 
technicians were required to initially reach all 239 patients. The PRO algorithm 
identified 68 patients (28%) experiencing problems that either restricted posses-
sion or limited adherence to the prescribed drug. Remediation resulted in a posi-
tive outcome for 65 patients (95%) who were then able to initiate or continue their 
prescribed treatment. CONCLUSIONS: PROs are believed to be a critical component 
of patient centered care. Incorporating PROs into daily practice is being actively 
studied. This pilot affirms that direct patient engagement via PRO can successfully 
overcome barriers to initiation of and adherence to prescribed treatment distributed 
by a specialty pharmacy.
PHS90
geograPHIc PatternS of Self-rePorted lIfetIme dePreSSIon dIagnoSIS
Tobo B.B., Adjei Boakye E., Buchanan P.
Saint Louis University, Saint Louis, MO, USA
OBJECTIVES: Depressive and anxiety disorders are the most common mental dis-
orders and often lead to costly mental distress in the US. The aim of this study was 
to determine if there are variations in the geographic distribution of self-reported 
lifetime depression using data from the 2012 Behavior Risk Factor Surveillance 
System (BRFSS). METHODS: Data were from the 2012 BRFSS, a cross-sectional ran-
dom-digit-dialed telephone survey of 475,687 noninstitutionalized adult population 
aged 18 years or older. The outcome variable was self-reported depression and the 
independent variable was geographic region as defined by the US Census Bureau 
(Midwest, Northeast, South, and West). A logistic regression model was constructed 
to examine the association between geographic region and socio-demographic fac-
tors and depression. RESULTS: There was a significant relationship between geo-
graphic region and lifetime depression in the bivariate analysis (p < 0.0001). After 
adjusting for the effects of other variables, geographic region was not significantly 
associated with lifetime depression. However, there was a significant relationship 
between geographic region and race in a bivariate analysis (p < 0.0001). Therefore, 
race was removed from the multivariate model. Thereafter, geographic region 
became significantly associated with lifetime depression (p < 0.0001). Participants 
living in the West and Northeast regions were 1.14 (95% CI, 1.06 – 1.18) and 1.11 (95% 
CI, 1.05 – 1.18) more likely to report lifetime depression compared to participants liv-
ing in the South. The Midwest region was not significantly associated with lifetime 
depression. CONCLUSIONS: There was no association between lifetime depres-
sion and geographic region with race in the model, but the association became 
significant after removing race. Because removing race resulted in a significant 
association, racial distribution may be more indicative of lifetime depression than 
geographic region. Public health services should consider the racial distribution of 
a geographic region when addressing the burden of lifetime depression.
migraineurs with or without N/V using Chi-square test. Adjusting for demographic 
and comorbidity differences, generalized linear models were conducted to compare 
HRU. RESULTS: Of the N= 7855 migraine participants, 58% reported N/V symptoms, 
female= 73%, white= 72%, mean age= 41.8 (SD= 14.0), mean Charlson-comorbidity 
index= 0.55 (SD= 1.26) and mean migraine episodes (past 30 days)= 3.27(SD= 5.33). 
Compared with migraineurs without N/V, significantly greater proportion of migra-
neurs with N/V reported depressive symptoms (39.2% vs 45.2%, p< 0.001 ), sleep 
problems (e.g. sleep difficulty, 43.6% vs 54.1%; daytime sleepiness, 30.9% vs 40.4%; 
poor sleep quality, 28.9% vs 38.9%; nighttime awakening, 33.9% vs 44.2%, all p< 0.001). 
Mean emergency room (ER) visits increased significantly by about 20% in migraneurs 
with N/V than without N/V [0.48 (95% CI = 0.41, 0.57) vs 0.38, [95% CI= 0.32, 0.45]; 
p< 0.01). Between migraineurs with and without N/V, no significant increase in the 
mean number of physician [5.24 (95% CI = 4.82, 5.69) vs 4.93 (95% CI= 4.54, 5.35); 
p= 0.06] and hospital visits [0.20 (95% CI = 0.16, 0.25) vs 0.19 (95% CI= 0.15, 0.24), 
p= 0.65] were detected. CONCLUSIONS: Migraineurs with N/V reported worsened 
sleep and depressive symptom outcomes, and higher ER visits than those with-
out N/V. Future research must evaluate the relationship of N/V severity on these 
outcomes. Study findings highlight opportunities for treatment options that may 
alleviate these unmet medical needs in migraineurs with N/V.
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OBJECTIVES: Depressive and anxiety disorders are the most common mental disor-
ders and are very common among individuals with a history of military service. The 
aims of this study were to examine the prevalence of depression among respondents 
with a history of military service, and examine if self-reported lifetime depression 
diagnosis in veterans differs by the major conflicts/war they served in, using the 
2012 Behavior Risk Factor Surveillance System (BRFSS). METHODS: 28,077 partici-
pants with a history of military service from 2012 BRFSS were used for the analysis. 
The outcome variable was self-reported lifetime depression and the independent 
variable was researcher defined conflict era using participant age and a positive 
reply to veteran status. These variables were used to group participants into the 
different conflicts in history (World War II, Korean, Vietnam, and the Gulf Wars). 
A logistic regression model was constructed to evaluate the association between 
conflict era and socio-demographic factors and depression. RESULTS: Depression 
prevalence among veterans was 15.1%. The distribution of conflict era was World 
War II (8.3%), Vietnam War (12.8%), Vietnam War (39.1%) and Gulf War (39.8%). After 
controlling for the effects of other variables, veteran participants in the Vietnam War 
and Gulf War were 3.13 (95% CI, 1.46 – 1.63) and 2.55 (95% CI, 1.07 – 1.27) times more 
likely to report a lifetime depression diagnosis compared to World War II veterans 
respectively. However, veterans that participated in the Korean War were not signifi-
cantly associated with lifetime depression. CONCLUSIONS: Depression rates vary 
by conflict era among war veterans. Understanding the burden of depression among 
veterans that participated in different conflict eras provides insightful distribution 
of clinical and programmatic resources. Future studies should attempt to use VA 
data to effectively include veteran or active duty status, dates of service, branch of 
service, combat exposure, trauma exposure, and physician diagnosed depression.
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OBJECTIVES: Patient-reported outcomes (PROs) are critical to advancing patient cen-
tered care. Recording PROs in real-time concurrent with clinician-reported outcomes 
represents the most direct and accurate comparative assessments of disease and 
treatment impact. This study sought to compare patient-generated global assessment 
(PGA) and physician global assessment (PhGA) rheumatoid arthritis (RA) scores to 
determine patient-physician discordance for rates of disease and treatment impact 
on perceived well-being. METHODS: From 1/1/2012 to 12/31/2013, 79 rheumatolo-
gists in 35 practices participating in a payer-sponsored rheumatologist-developed 
RA pathway program incorporated use of a point-of-care DST, which required a clini-
cal disease activity index (CDAI) assessment at each physician visit. Components 
of the CDAI included PhGA and PGA scores, which were captured over the study 
period; lower scores are associated with better patient status. Paired t-tests and lin-
ear regression were used to analyze and compare scores for discordance. RESULTS: 
3406 patients had 9769 physician visits during the study period where both PGA 
and PhGA were captured. The mean age of the study population was 57 years; 77% 
of patients were female. The unadjusted mean PGA score was 3.26 (standard devia-
tion [SD]: 2.69) compared to the mean PhGA score of 2.51 (SD: 2.24); p< .0001. Linear 
regression revealed that for every 1-unit increase in PGA score, the PhGA score only 
increased by 0.69 (p< .0001); the R-squared value was 0.326, indicating a moderate 
correlation. CONCLUSIONS: This research affirms the role of PRO at point of care. Our 
data demonstrate discordance between physician and patient global assessments. 
Although there was a linear correlation between the PGA and PhGA scores, the sig-
nificant difference in mean scores indicates that physicians underestimated disease 
severity and treatment related adverse events and their impact on patient perceived 
well-being. Additional analyses, including adjustment for covariates, are planned.
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